ReviewCellular and molecular life sciences : CMLS2016
Hypoxia-regulated mechanisms in the pathogenesis of obesity and non-alcoholic fatty liver disease.
Review in Cellular and molecular life sciences : CMLS, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- The effects of hypoxic versus normoxic exercise training on body composition, cardiometabolic health markers, and functional performance in adults: a systematic review and meta-analysis.BMC sports science, medicine & rehabilitation · 2026Pooled it
- Construction and Validation of a TyG-ALT-Based Diagnostic Risk-Stratification Model for Metabolic-Associated Fatty Liver Disease in Patients with Obstructive Sleep Apnea.Journal of clinical medicine · 2026Article
- Network Pharmacology Analysis of Glycyrrhetinic Acid in Metabolic Dysfunction-Associated Steatotic Liver Disease.Metabolites · 2026Article
- Review
- Feeding the invaders: how metabolic imbalance shapes infection and biofilm development.FEMS microbiology reviews · 2026Review
- Effects of a High-Fat Diet and a Plant Extract Composition on Extracellular Matrix Remodeling in Rat Liver.Bulletin of experimental biology and medicine · 2026Article
- Hypoxia-inducible factors in the immunometabolism of metabolic dysfunction-associated steatotic liver disease (MASLD): molecular mechanisms and therapeutic implications.Frontiers in physiology · 2026Article
- Relationship between body mass index, gray matter volume and peripheral inflammation in patients with post-COVID condition.Brain, behavior, & immunity - health · 2025Article
- Targeting Regulation of Macrophage to Treat Metabolic Disease: Role of Phytochemicals.Cell proliferation · 2025Review
- A new investigation of nonalcoholic fatty liver disease: Effects of hypoxia on mitochondrial function and lipid droplet autophagy.PloS one · 2025Article
- The role of adipose tissue and subsequent liver tissue hypoxia in obesity and early stage metabolic dysfunction associated steatotic liver disease.International journal of obesity (2005) · 2024Article
- Hematologic traits and primary biliary cholangitis: a Mendelian randomization study.Journal of human genetics · 2023Article
- 4-PBA inhibits hypoxia-induced lipolysis in rat adipose tissue and lipid accumulation in the liver through regulating ER stress.Food science & nutrition · 2023Article
- Inflammatory processes involved in NASH-related hepatocellular carcinoma.Bioscience reports · 2023Review
- Programmed cell death and lipid metabolism of macrophages in NAFLD.Frontiers in immunology · 2023Review
- Obesity contributes to hepatocellular carcinoma development via immunosuppressive microenvironment remodeling.Frontiers in immunology · 2023Review
- Profiles of transcriptome and metabolic pathways after hypobaric hypoxia exposure.Proteome science · 2022Article
- Review
- Review
- Mechanism and Basis of Traditional Chinese Medicine Against Obesity: Prevention and Treatment Strategies.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pandemic rise in obesity has resulted in an increased incidence of metabolic complications. Non-alcoholic fatty liver disease is the hepatic manifestation of the metabolic syndrome and has become the most common chronic liver disease in large parts of the world. The adipose tissue expansion and hepatic fat accumulation characteristics of these disorders compromise local oxygen homeostasis. The resultant tissue hypoxia induces adaptive responses to restore oxygenation and tissue metabolism and cell survival. Hypoxia-inducible factors (HIFs) function as master regulators of this hypoxia adaptive response, and are in turn hydroxylated by prolyl hydroxylases (PHDs). PHDs are the main cellular oxygen sensors and regulate HIF proteasomal degradation in an oxygen-dependent manner. HIFs and PHDs are implicated in numerous physiological and pathological conditions. Extensive research using genetic models has revealed that hypoxia signaling is also a key mechanism in adipose tissue dysfunction, leading to adipose tissue fibrosis, inflammation and insulin resistance. Moreover, hypoxia affects liver lipid metabolism and deranges hepatic lipid accumulation. This review summarizes the molecular mechanisms through which the hypoxia adaptive response affects adipocyte and hepatic metabolism, and the therapeutic possibilities of modulating HIFs and PHDs in obesity and fatty liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.